- Home
- TILE vs COLL Comparison
TILE vs COLL Comparison
Compare TILE & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TILE
- COLL
- Stock Information
- Founded
- TILE 1973
- COLL 2002
- Country
- TILE United States
- COLL United States
- Employees
- TILE N/A
- COLL N/A
- Industry
- TILE Home Furnishings
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- TILE Consumer Discretionary
- COLL Health Care
- Exchange
- TILE Nasdaq
- COLL Nasdaq
- Market Cap
- TILE 1.1B
- COLL 864.7M
- IPO Year
- TILE N/A
- COLL 2015
- Fundamental
- Price
- TILE $20.45
- COLL $28.15
- Analyst Decision
- TILE Buy
- COLL Strong Buy
- Analyst Count
- TILE 1
- COLL 5
- Target Price
- TILE $30.00
- COLL $43.60
- AVG Volume (30 Days)
- TILE 425.5K
- COLL 340.0K
- Earning Date
- TILE 05-02-2025
- COLL 05-08-2025
- Dividend Yield
- TILE 0.20%
- COLL N/A
- EPS Growth
- TILE 44.62
- COLL 43.56
- EPS
- TILE 1.46
- COLL 1.86
- Revenue
- TILE $1,323,328,000.00
- COLL $631,449,000.00
- Revenue This Year
- TILE $4.21
- COLL $19.96
- Revenue Next Year
- TILE $5.25
- COLL $3.93
- P/E Ratio
- TILE $13.61
- COLL $14.69
- Revenue Growth
- TILE 5.41
- COLL 11.41
- 52 Week Low
- TILE $14.13
- COLL $23.23
- 52 Week High
- TILE $27.34
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- TILE 66.08
- COLL 59.37
- Support Level
- TILE $18.77
- COLL $26.72
- Resistance Level
- TILE $20.42
- COLL $27.70
- Average True Range (ATR)
- TILE 0.64
- COLL 1.02
- MACD
- TILE 0.26
- COLL 0.24
- Stochastic Oscillator
- TILE 100.00
- COLL 78.66
About TILE Interface Inc.
Interface Inc is engaged in the design, production, and sale of carpet tiles. It also provides Luxury Vinyl tiles and rubber flooring. The company mainly targets corporate and noncorporate office markets, including government, education, healthcare, hospitality, and retailers. Its geographical segments include the Americas, Europe, and Asia-Pacific. It has two operating and reportable segments- namely Americas (AMS) and Europe, Africa, Asia and Australia (collectively EAAA). Key revenue is generated from AMS segment.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.